Nougaret Stephanie, Gormly Kirsten, Lambregts Doenja M J, Reinhold Caroline, Goh Vicky, Korngold Elena, Denost Quentin, Brown Gina
From the Department of Radiology, Montpellier Cancer Institute, University of Montpellier, 208 av des Apothicaires, 34090 Montpellier, France (S.N.); PINKCC Laboratory, Montpellier Cancer Research Institute, University of Montpellier, Montpellier, France (S.N.); Jones Radiology, South Australia, Australia (K.G.); The University of Adelaide, South Australia, Australia (K.G.); Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands (D.M.J.L.); GROW School for Oncology and Reproduction, University of Maastricht, Maastricht, the Netherlands (D.M.J.L.); Department of Radiology, McGill University, Montreal, Quebec, Canada (C.R.); Department of Radiology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom (V.G.); School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, United Kingdom (V.G.); Department of Radiology, Oregon Health & Science University, Portland, Ore (E.K.); Bordeaux Colorectal Institute, Bordeaux, France (Q.D.); Department of Radiology, Royal Marsden, London, United Kingdom (G.B.); Department of Radiology, Imperial College London, London, United Kingdom (G.B.).
Radiology. 2025 Jan;314(1):e232838. doi: 10.1148/radiol.232838.
Over the past decade, advancements in rectal cancer research have reshaped treatment paradigms. Historically, treatment for locally advanced rectal cancer has focused on neoadjuvant long-course chemoradiotherapy, followed by total mesorectal excision. Interest in organ preservation strategies has been strengthened by the introduction of total neoadjuvant therapy with improved rates of complete clinical response. The administration of systemic induction chemotherapy and consolidation chemoradiotherapy in the neoadjuvant setting has introduced a new dimension to the treatment landscape and patients now face a more intricate decision-making process, given the expanded therapeutic options. This complexity underlines the importance of shared decision-making and brings to light the crucial role of radiologists. MRI, especially high-spatial-resolution T2-weighted imaging, is heralded as the reference standard for rectal cancer management because of its exceptional ability to provide staging and prognostic insights. A key evolution in MRI interpretation for rectal cancer is the transition from the DISTANCE mnemonic to the more encompassing DISTANCED-DIS, distal tumor boundary; T, T stage; A, anal sphincter complex; N, nodal status; C, circumferential resection margin; E, extramural venous invasion; D, tumor deposits. This nuanced shift in the mnemonic captures a wider range of diagnostic indicators. It also emphasizes the escalating role of radiologists in steering well-informed decisions in the realm of rectal cancer care.
在过去十年中,直肠癌研究的进展重塑了治疗模式。从历史上看,局部晚期直肠癌的治疗重点是新辅助长程放化疗,随后进行全直肠系膜切除术。随着新辅助全治疗的引入以及完全临床缓解率的提高,人们对器官保留策略的兴趣得到了增强。在新辅助治疗中给予全身诱导化疗和巩固放化疗为治疗格局带来了新的维度,鉴于治疗选择的增加,患者现在面临着更为复杂的决策过程。这种复杂性凸显了共同决策的重要性,并揭示了放射科医生的关键作用。MRI,尤其是高空间分辨率T2加权成像,因其在提供分期和预后见解方面的卓越能力,被誉为直肠癌管理的参考标准。直肠癌MRI解读的一个关键进展是从DISTANCE记忆法向更全面的DISTANCED-DIS转变,其中D代表远端肿瘤边界;I代表T分期;S代表肛门括约肌复合体;T代表T分期;A代表肛门括约肌复合体;N代表淋巴结状态;C代表环周切缘;E代表壁外静脉侵犯;D代表肿瘤结节。记忆法的这种细微转变涵盖了更广泛的诊断指标。它还强调了放射科医生在指导直肠癌护理领域做出明智决策方面日益重要的作用。